Clinical Trials Logo

Erythema Dyschromicum Perstans clinical trials

View clinical trials related to Erythema Dyschromicum Perstans.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04233749 Recruiting - Clinical trials for Lichen Planus Pigmentosus

The Efficacy of Tranexamic Acid in the Treatment of Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans

Start date: March 17, 2020
Phase: Phase 2
Study type: Interventional

There are currently no effective treatments for lichen planus pigmentosus (LPP) and erythema dyschromicum perstans (EDP). Tranexamic acid, which may downregulate pigmentation through a reduction in plasmin, has been shown to decrease pigmentation in patients with melasma, another pigmentary disorder. Given that LPP, EDP, and melasma are all disorders of pigmentation with dermal involvement, it is possible that tranexamic acid can also reduce pigmentation in LPP and EDP as well.